ClinicalTrials.gg
RecruitingNCT04045587ISARUpdated May 1, 2026

International Severe Asthma Registry: Canadian Cohort

An observational study in Severe Asthma, sponsored by University of British Columbia. Recruiting at 12 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Started Nov 2018; still recruiting 8 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
714
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Asthma by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Asthma · University of British Columbia.

Started
2018
with 2 others
Observational
6 of 20
2 open now
Registered
14th of 20
by date

Among the 20 studies in Asthma by University of British Columbia, this one is one of 3 that started in 2018, is one of 6 observational ones, and was the 14th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 20 studies in Asthma by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Asthma by University of British Columbia, or all of them as a file.
02

Study summary

The International Severe Asthma Registry is a global initiative looking to ensure that the care of people with severe asthma will continue to improve by collecting detailed information about the health and treatment of as many people with the disease as possible. The study will gather anonymized longitudinal real-life data for participants with severe asthma for five years. The purpose of the registry is to track the progress of participants and determine how well they are responding to treatment. Medical research using data from the registry will give the investigators a better understanding of severe asthma and help the investigators develop and improve the care and treatment for severe asthma participants. The Canadian cohort of the registry will collect information from Canadian participants with severe asthma across seven different sites.

Read the detailed description

Study staff will collect medical information through reviewing participant medical charts and interviewing participants about their health/asthma. The information collected includes birth date, gender, ethnicity, height/weight, body mass index, medical history (smoking history and exacerbation history), current and past asthma related medications, and any recent test results available pertaining to blood work, lung function, allergen skin prick, and imaging. This information will be collected at the baseline visit, and then once a year at a follow up visit, for five years (total of five visits).

Participants will be assigned a unique study number to protect the confidentiality of their personal health care information. All study data will be de-identified and then stored in a secure information management system, hosted at the study sponsor, Optimum Patient Care Global Limited in Cambridge, United Kingdom. Participant identities will always be kept confidential and will not be included in any research that is published. Data collected across the Canadian sites will be used to find ways to improve asthma treatments in Canada, to report on current patterns of managing severe asthma in Canada, to identify different sub-groups of severe asthma, and to carry out various medical research to understand asthma better and develop new treatments.

Research records and health or other source records may be inspected in the presence of the Principal Investigator or by representatives of the University of British Columbia's Clinical Research Ethics Board for the purpose of monitoring the research. No information or records that disclose participants' identities will be published without subject consent, nor will any information or records that disclose participants' identities be removed or released without subject consent unless required by law.

03

Conditions studied

  • Severe Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be selected from respirology/pulmonary clinics across Canada. Participants will be identified and recruited by the study investigators and study staff based on their clinical presentation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 18 years or older
  • Participants receiving treatment according to GINA Step 5 or uncontrolled in GINA Step 4 (uncontrolled is defined as having severe asthma symptoms or frequent exacerbations)

Exclusion criteria

Exclusion Criteria:

-Participants with mild to moderate asthma

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
714 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Severe Asthma Participants

    Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.

06

What researchers measure

Primary outcomes

  1. Blood eosinophil counts

    10\^9/L

    Time frame: Past 12 months

  2. Blood Immunoglobulin E (IgE) counts

    kilo unit/L

    Time frame: Past 12 months

  3. Fractional exhaled nitric oxide level

    parts per billion

    Time frame: Past 12 months

  4. Start and end dates of oral corticosteroid medication

    Day/Month/Year for start and end dates if available

    Time frame: Prior to baseline visit

  5. Asthma Control

    Assessed through the Global Initiative for Asthma (GINA) Questionnaire

    Time frame: Past 4 weeks

  6. Start and end dates of biologic medications such as anti-interleukin-5, anti-immunoglobulin E, or anti-interleukin-4 treatments (if relevant)

    Day/Month/Year for start and end dates if available

    Time frame: Prior to baseline visit

  7. Reason for switching biologic medication (if relevant)

    Options include: lack of clinical efficacy, side effects, biologic access restriction, and patient preference

    Time frame: Past 12 months

  8. Start and end dates of all asthma related inhaled medications

    Day/Month/Year for start and end dates if available

    Time frame: Prior to baseline visit

  9. Number of asthma exacerbations requiring rescue steroids

    Severe asthma exacerbations are defined as events that require urgent action (rescue steroids) by the participant and physician to prevent a serious outcome

    Time frame: Past 12 months

  10. Number of emergency room visits for asthma

    Total number of visits

    Time frame: Past 12 months

  11. Number of hospital admissions for asthma

    Total number of admissions

    Time frame: Past 12 months

  12. Spirometry test results for Forced Vital Capacity (FVC)

    Pre- and post-bronchodilator FVC results in litres

    Time frame: Past 12 months

  13. Spirometry test results for Forced Expiratory Volume in One Second (FEV1)

    Pre- and post-bronchodilator FEV1 results in litres

    Time frame: Past 12 months

07

Study locations

9 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for Dec 2027, 109 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2019
First posted
Aug 5, 2019
StartActual
Nov 6, 2018
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04045587
Responsible party
Celine Bergeron (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Aug 5, 2019
Start date
Nov 6, 2018
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Shelley Abercromby
Contact
Shelley.Abercromby@vch.ca
(604) 875-4111 ext. 62500
Maria Naval
Contact
Maria.Naval@vch.ca
604-875-5697
Celine Bergeron
principal investigator · University of British Columbia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion